Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02478775 · ClinicalTrials.gov registry record · NA

Dysregulation of FSH in Obesity: Functional and Statistical Analysis

A NA study, sponsored by University of Colorado, Denver.

Completed
Registry status
NA
Development phase
99
Enrollment target

NCT02478775: Completed NA study, sponsored by University of Colorado, Denver.

NCT02478775 is a NA study that has completed, run by University of Colorado, Denver. The registered enrollment target is 99 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02478775, a NA study, has completed, sponsored by University of Colorado, Denver.

COMPLETED
Registry status
NA
Development phase
99 participants
Enrollment target

Study Summary

Excess maternal weight, especially obesity, influences almost every aspect of fertility, from conception to problems during pregnancy. The investigators will use novel statistical methods to clarify the hormonal changes behind reproductive health conditions. A better understanding of reproductive hormonal changes in obese women may offer a way to identify new treatments.

Primary Outcome

This is defined as the maximum hormone value during Day 1 of the study subtracted from the maximum hormone value during Day 2.

Interventions

  • DRUG recombinant FSH
  • DRUG Cetrorelix
  • DRUG Degarelix (GnRH antagonist)

Trial Details

FieldValue
Enrollment Target 99 participants
Start Date 2015-07
Est. Completion 2021-06-30
Phase NA
University of Colorado, Denver

1,283 total trials

What the finished NCT02478775 record still lists

NCT02478775 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).

The record links to 0 conditions, and to 3 interventions - of which recombinant FSH is the first listed.

NCT02478775 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02478775 about?

NCT02478775 is a clinical study titled "Dysregulation of FSH in Obesity: Functional and Statistical Analysis". Excess maternal weight, especially obesity, influences almost every aspect of fertility, from conception to problems during pregnancy. The investigators will use novel statistical methods to clarify the hormonal changes behind reproductive health conditions. A better understanding of reproductive ho...

What is the current status of trial NCT02478775?

This trial is currently completed. It is a NA study. The enrollment target is 99 participants. The study started on 2015-07. Estimated completion is 2021-06-30.

What interventions are being tested in trial NCT02478775?

The interventions under investigation include: recombinant FSH (DRUG), Cetrorelix (DRUG), Degarelix (GnRH antagonist) (DRUG).

Who is sponsoring clinical trial NCT02478775?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02478775's enrollment target sits among peer trials

99 920th of 2000 higher than 1,079 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03965234 · 99 participants · Phase 1

    Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases

  • NCT04022616 · 99 participants

    Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients

  • NCT04042844 · 99 participants · Phase 2

    A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)

  • NCT04143724 · 99 participants · Phase 2

    Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02478775, the US trial registry maintained by the National Library of Medicine. NCT02478775 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.